AOD-9604
/ Modified fragment of human growth hormone amino acids 176-191ALIAS · Modified human GH fragment 176-191
Terms in this page you can click for a plain-English popup: , , , , , , , .
Developed by Metabolic Pharmaceuticals through Phase 2 for obesity; did not meet efficacy endpoints at doses studied. Subsequently marketed as a cosmetic ingredient in some jurisdictions. Modest human data.
AOD-9604 is a modified analog of the C-terminus of human growth hormone (residues 176-191). Proposed to preserve the lipolytic activity of GH without the metabolic and mitogenic effects tied to GH receptor activation. Mechanism claimed to be independent of GH-receptor pathway, though the specific target is not well established.
Metabolic Pharmaceuticals conducted human obesity trials through Phase 2 in the mid-2000s. Trial endpoints on weight loss were not met at doses studied. Subsequent marketing shifted from obesity therapeutic to cosmetic ingredient.
Short-term trials reported generally acceptable tolerability with mild GI and injection-site reactions. Long-term human safety data at research-chemical doses is not available.
Regulatory status
- FDA status:
- Not FDA-approved
Phase 2 obesity trial did not meet efficacy endpoints; subsequent repositioning as a cosmetic ingredient undermines the clinical claims that still circulate in peptide-marketing literature. The mechanism independent of GH receptor remains mechanistically underspecified in the peer-reviewed literature.